Evidence map›Paper›PMID 40646356›Full record

ReviewCell biology and toxicology2025

Advances in hybrid hydrogel design for biomedical applications: innovations in drug delivery and tissue engineering for gynecological cancers.

Hua Chang, Heng Wei, Yue Qi, Silu Ding, Hui Li, Si Si

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hua Chang *Department Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Heng Wei *Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Liaoning, China.
Yue Qi *Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Liaoning, China.
Silu DingDepartment of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China. dsl1108@hotmail.com.
Hui LiDepartment Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, China. yidalihui@163.com.
Si SiDepartment of Obstetrics, The First Hospital of China Medical University, Shenyang, China. ss_cmu@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hybrid hydrogels have emerged as multifunctional biomaterials for targeted drug delivery and tissue engineering in gynecologic oncology. In this review, we summarize recent advances in the design of hybrid hydrogels that combine polymer networks with nanomaterials to achieve tunable stimuli-responsiveness, enhanced mechanical strength, and improved biocompatibility. For example, preclinical studies of folate-conjugated liposomal doxorubicin have demonstrated enhanced accumulation and antitumor efficacy in ovarian cancer models, while growth factor-loaded hydrogel scaffolds have supported endometrial repair in rodent models. We discuss strategies for optimizing drug loading, controlling spatiotemporal release profiles in response to tumor-specific cues (such as pH or enzyme activity), and customizing scaffold architecture for patient-specific regenerative needs. Implementation challenges-including efficient encapsulation of multiple cargos, precise control over degradation rates, and scale-up for clinical manufacturing-are critically examined. Finally, we outline future directions, including multifunctional platforms that integrate real-time monitoring with combined chemo-immunotherapy and approaches to address regulatory and translation hurdles. This evidence-based analysis highlights how hybrid hydrogels can advance precision therapy and regenerative medicine for gynecologic cancers while there is a need for further validation in clinical settings.

Indexed as

Drug Delivery SystemsGenital Neoplasms, FemaleHydrogelsTissue EngineeringAnimalsBiocompatible MaterialsFemaleHumansBiocompatible MaterialsHydrogelsDrug deliveryGynecological cancersHybrid hydrogelsTissue engineering

Identifiers

PMID40646356
PMCPMC12254095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.